Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 944-699-9 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The ‘No Observed Adverse Effect Level’ (NOAEL) for systemic toxicity when administered repeated for 28 days was considered to be 1000 mg/kg bw/day.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- High quality GLP compliant guideline study
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Repeated dose toxicity: oral
Currently no study to assess repeated dose oral toxicity of Disperse Blue 056 is available. However, source substance Disperse Blue 054/077 was evaluated for the potential to cause adverse effects on repeated exposure in a combined repeated dose toxicity study with reproductive and developmental screening via oral route.
In this study, the Disperse Blue 054/077 was administered by gavage to three groups, each of twelve male and twelve female Wistar Han™:RccHan™:WIST strain rats, for up to eight weeks (including a two week pre-pairing phase, pairing, gestation and early lactation for females), at dose levels of 100, 300 and 1000 mg/kg bw/day. A control group of twelve males and twelve females was dosed with vehicle alone (Polyethylene glycol 400). No toxicologically significant adverse effects in terms of clinical signs, behavioural assessments, body weight change and food and water consumption were observed during the study. Similarly, gross necropsy examination and histopathological evaluation of selected tissues also did not reveal any adverse effects caused by the administration of the test item. Hence, it was concluded that the oral administration of FAT 92504/C TE to rats by gavage, at dose levels of 100, 300 and 1000 mg/kg bw/day, did not result in any significant toxicological effects. The ‘No Observed Adverse Effect Level’ (NOAEL) for systemic toxicity was therefore considered to be 1000 mg/kg bw/day for either sex.
Repeated dose toxicity: inhalation
Currently no study to assess repeated dose inhalation toxicity of Disperse Blue 056 is available.The test substance has low volatility as its melting point >300 °C, so the potential for the generation of inhalable forms is low. The use of this substance will not result in aerosols, particles or droplets of an inhalable size, so exposure to humans via the inhalation route will be unlikely to occur. Further absence of adverse effects from repeated exposure of test animals via the oral route in a combined repeated dose toxicity study with reproductive and developmental screening with source substance Disperse Blue 054/077, suggests the substance to have low toxicity. Hence no significant toxicity is expected via the inhalation route and safety for human health can be estimated via route to route extrapolation. Further, production and spray drying is performed in closed processes without isolation of reaction products. Isolated product is present in dust free granules (non-dusty solid). Taking into consideration all the above arguments, no repeated dose inhalation toxicity study was performed.
Repeated dose toxicity: dermal
Currently no study to assess repeated dose dermal toxicity of Disperse Blue 056 is available.However, it hasvery low solubility in water (<1 mg/L), hence dermal uptake is likely to be low asthe substance isconsidered as not sufficiently soluble in water to partition from the stratum corneum into the epidermis.Further absence of adverse effects from repeated exposure of test animals via the oral route in a combined repeated dose toxicity study with reproductive and developmental screening with source substance Disperse Blue 054/077, suggests the substance to have low toxicity. Hence no significant toxicity is expectedviathe dermal route and safety for human health can be estimatedviaroute to route extrapolation. Similarly absence of systemic toxicity or mortality in skin irritation as well as sensitization studies with target substance, supports the conclusion that no adverse effects are expectedviadermal route. Further experience with similar chemical substances has demonstrated that it is very unlikely that toxicity related to the intrinsic properties of the test item only show up upon dermal exposure and not after systemic application, hence further experiments to assess dermal toxicity are not taken into account.
Justification for classification or non-classification
Based on the above discussion, FAT 92504 does not warrant classification according to CLP (Regulation EC No. 1272/2008) criteria.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.